Seattle genetics announces positive topline results from phase 2 clinical trial of tisotumab vedotin

Seattle genetics announces positive topline results from phase 2 clinical trial of tisotumab vedotin in recurrent or metastatic cervical cancer.seattle genetics - look forward to discussing with fda potential submission of bla to support accelerated approval of tisotumab vedotin.

SGEN Ratings Summary

SGEN Quant Ranking